Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Added pomalidomide reduced risk of progression, death in myeloma
Richardson PG et al. ASCO 2018, Abstract 8001.
Key clinical point: For myeloma patients previously exposed to lenalidomide, the three-drug regimen outperformed the two-drug regimen.
Major finding: Risk of disease progression or death was reduced by 39% with pomalidomide plus bortezomib and low‐dose dexamethasone (PVd), compared with use of bortezomib and low-dose dexamethasone alone (Vd).
Study details: The phase 3 OPTIMISMM trial including 559 patients who had received prior therapy with at least two cycles of lenalidomide.
Disclosures: The study was supported by Celgene. Dr. Richardson reported advisory board work for Celgene, Novartis, Oncopeptides, Janssen, Amgen, and Takeda and research funding from Bristol-Myers Squibb, Celgene, and Takeda.
Richardson PG et al. ASCO 2018, Abstract 8001.